Durable complete response of hepatocellular carcinoma after metronomic capecitabine.

作者: Luigi Bolondi , Giovanni Brandi , Stefania Di Girolamo , Elisabetta Nobili , Francesco de Rosa

DOI: 10.1700/548.6527

关键词:

摘要: Background. Hepatocellular carcinoma (HCC) is a highly vascular tumor which poorly responsive to standard systemic chemotherapy. Recently, various antiangiogenic targeted agents have shown promising activity at different levels of evidence in patients with advanced HCC, suggesting that such treatments might be effective. Case report. Since chemotherapy administered metronomic schedules inhibits angiogenesis, we treated 64-year-old man HCC capecitabine. After only two months treatment the nodules disappeared on ultrasonography. This finding was confirmed by computed tomography scan. more than three years patient still minimal toxicity and maintains complete remission. Conclusions. Our case report suggests capecitabine may effective while being also well tolerated. important, given frequent comorbidities patients. Free full text available

参考文章(11)
Se Hoon Park, Yuna Lee, Sang Hoon Han, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Yeon Ho Park, Jeong Nam Lee, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, None, Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma BMC Cancer. ,vol. 6, pp. 3- 3 ,(2006) , 10.1186/1471-2407-6-3
Yehuda Z. Patt, Manal M. Hassan, Alvaro Aguayo, Ajay K. Nooka, Richard D. Lozano, Steven A. Curley, Jean-Nicolas Vauthey, Lee M. Ellis, Isac I. Schnirer, Robert A. Wolff, Chusilp Charnsangavej, Thomas D. Brown, Oral Capecitabine for the Treatment of Hepatocellular Carcinoma, Cholangiocarcinoma, and Gallbladder Carcinoma Cancer. ,vol. 101, pp. 578- 586 ,(2004) , 10.1002/CNCR.20368
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
V Boige, , J-L Raoul, J-P Pignon, O Bouché, J-F Blanc, L Dahan, J-L Jouve, N Dupouy, M Ducreux, Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. British Journal of Cancer. ,vol. 97, pp. 862- 867 ,(2007) , 10.1038/SJ.BJC.6603956
Simone Steinbild, Jann Arends, Michael Medinger, Brigitte Häring, Annette Frost, Joachim Drevs, Clemens Unger, Ralph Strecker, Jürgen Hennig, Klaus Mross, Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie. ,vol. 30, pp. 629- 635 ,(2007) , 10.1159/000110580
Urban Emmenegger, Robert S. Kerbel, Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and Perspectives Onkologie. ,vol. 30, pp. 606- 608 ,(2007) , 10.1159/000111479
Yuval Shaked, Urban Emmenegger, Shan Man, Dave Cervi, Francesco Bertolini, Yaacov Ben-David, Robert S. Kerbel, Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Blood. ,vol. 106, pp. 3058- 3061 ,(2005) , 10.1182/BLOOD-2005-04-1422
Joanna WY Ho, Roberta WC Pang, Cecilia Lau, Chris K Sun, Wan Ching Yu, Sheung Tat Fan, Ronnie TP Poon, None, Significance of circulating endothelial progenitor cells in hepatocellular carcinoma Hepatology. ,vol. 44, pp. 836- 843 ,(2006) , 10.1002/HEP.21353
Andrew Burroughs, Daniel Hochhauser, Tim Meyer, Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncology. ,vol. 5, pp. 409- 418 ,(2004) , 10.1016/S1470-2045(04)01508-6
Kathy D. Miller, Christopher J. Sweeney, George W. Sledge, Redefining the Target: Chemotherapeutics as Antiangiogenics Journal of Clinical Oncology. ,vol. 19, pp. 1195- 1206 ,(2001) , 10.1200/JCO.2001.19.4.1195